Enanta Pharmaceuticals Inc Dossier - Source-backed chat

Enanta Pharmaceuticals Inc

ENTANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.99

Intrinsic Value $8.41median of 2 methodsbased on filings through 30 Sep 2025

Market Price $12.84Price as of 1 Oct 2026

OvervaluedIntrinsic value is 35% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $374M

Enterprise Value $185.2M

Shares Outstanding 29.1M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Enanta Pharmaceuticals is a clinical-stage biotechnology company transitioning from a historically royalty-dependent model (via its AbbVie HCV partnership) to a robust, wholly-owned pipeline focused on viral infections and immunology. The company's investment thesis is anchored by its late-stage RSV candidate, zelicapavir, which has a clear, FDA-aligned registrational pathway, and a rapidly expanding oral immunology portfolio targeting high-value indications like chronic spontaneous urticaria and atopic dermatitis. Backed by a strong cash runway extending into fiscal 2029, Enanta offers an attractive risk-reward profile with multiple near-term clinical catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$19.00

Mean target$21.17

High · most bullish analyst$28.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

In the bear case, zelicapavir experiences clinical or regulatory delays, pushing back the expected 2027 topline data readouts. The Federal Circuit rules against Enanta in the Pfizer patent litigation, eliminating potential legal windfalls. Furthermore, EDP-978 displays safety or tolerability issues in its Phase 1 trial, limiting its development path and increasing the company's reliance on its depleting cash reserves.

Base CaseCentral scenario

In the base case, Enanta successfully initiates its registrational Phase 2b/3 trial for zelicapavir in high-risk adults in 4Q 2026 and its Phase 2b pediatric trial in 3Q 2026. Topline Phase 1 data for the oral KIT inhibitor EDP-978 is delivered in 4Q 2026, demonstrating favorable safety and biomarker activity. The company maintains its cash runway into fiscal 2029, and the market begins to price in the late-stage potential of its RSV franchise.

Bull CaseUpside scenario

Enanta's bull case centers on its wholly-owned clinical pipeline in virology, specifically its two oral RSV antivirals, zelicapavir (an N-protein inhibitor) and EDP-323 (an L-protein inhibitor), both in Phase 2 development targeting a high-demand market with no approved treatments for active RSV infection. Additionally, the company has a strong balance sheet with approximately $260 million in cash providing runway into late 2027 or early 2028, ongoing patent litigation against Pfizer over COVID-19 therapeutics that could yield a significant settlement or royalty stream, and stable baseline cash flows from its Hepatitis C royalty agreement with AbbVie.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA-aligned registrational pathway for zelicapavir, which could become the first approved oral antiviral for RSV.
Strong financial position with approximately $241.9 million in cash and marketable securities (as of Dec 31, 2025), providing a runway into fiscal 2029.
Rapidly advancing oral immunology pipeline (KIT, STAT6, and MRGPRX2 inhibitors) targeting large, established markets.
Potential near-term catalyst from the Pfizer patent litigation appeal decision expected in 3Q 2026.

Key Investment Risks

High clinical development risk inherent to clinical-stage biotechnology companies.
Depleting royalty streams from the AbbVie HCV partnership as the hepatitis C market matures.
Intense competition in the RSV and immunology spaces from larger, well-capitalized pharmaceutical companies.
Litigation risk associated with the ongoing patent dispute with Pfizer.

Thesis Invalidation Triggers

Failure to initiate the zelicapavir Phase 2b/3 adult trial by the end of 2026.
Unfavorable safety or efficacy signals in the EDP-978 Phase 1 trial.
A significant reduction in the projected cash runway due to unexpected operational or clinical cost overruns.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.